BioNTech Phase 3 trial of variant-adapted BNT162b2 COVID vaccine recruiting
BioNTech, with Pfizer as collaborator, is recruiting 700 participants for a Phase 3 study testing updated BNT162b2 vaccine candidates across pediatric and adult age groups.
One registry update this week covers a single ongoing BioNTech trial.
- A Phase 3 study of variant-adapted BNT162b2 vaccine candidates, sponsored by BioNTech SE with Pfizer as collaborator, is recruiting as of the last update posted September 28, 2026. The study aims to assess safety and effects of BNT162b2 vaccines in participants 5 through 64 years of age with risk factors for severe COVID-19, and in participants 65 years of age and older.1 The trial has an estimated enrollment of 700 participants, with Cohort 1 receiving a single age-appropriate dose of 30 mcg for those 12 years and older or 10 mcg for those 5 to 11 years old, targeting the 2026/2027 recommended COVID-19 strain.1 Primary completion is estimated for April 21, 2027.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.